Group 1 - The hair medical concept sector increased by 2.20%, ranking 6th among concept sectors, with 16 stocks rising, including Huailong Co., which hit the daily limit, and Zhendong Pharmaceutical, *ST Meigu, and Baicheng Pharmaceutical showing notable gains of 7.32%, 4.81%, and 3.56% respectively [1][2] - The sector saw a net inflow of 142 million yuan from main funds, with 11 stocks receiving net inflows, led by Huailong Co. with a net inflow of 134 million yuan, followed by Baicheng Pharmaceutical, Shuiyang Co., and Minsheng Health with net inflows of 34.48 million yuan, 18.79 million yuan, and 11.22 million yuan respectively [2][3] - In terms of fund inflow ratios, Huailong Co., Baicheng Pharmaceutical, and International Medicine had the highest net inflow rates of 31.08%, 11.58%, and 6.12% respectively [3] Group 2 - The top gainers in the hair medical concept sector included Huailong Co. with a daily increase of 10.00% and a turnover rate of 7.90%, and Baicheng Pharmaceutical with a 3.56% increase and a turnover rate of 10.97% [3][4] - Conversely, the top decliners included Jiu Zhi Tang, Neng Te Ke Ji, and Kang Hui Pharmaceutical, which fell by 1.06%, 0.62%, and 0.36% respectively [1][4] - The overall performance of the hair medical concept sector reflects a positive trend in investor sentiment and capital inflow, indicating potential growth opportunities within the sector [2][3]

Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]

临时公告 证券代码：000989 证券简称：九芝堂 公告编号：2025-046 九芝堂股份有限公司 关于全资子公司研发新药启动 II 期临床试验的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导 性陈述或者重大遗漏负连带责任。 2025 年 5 月 24 日，九芝堂股份有限公司(以下简称"公司"或"本公司") 全资子公司牡丹江友搏药业有限责任公司(以下简称"友搏药业")与牵头组长 单位复旦大学附属华山医院和参研的四川大学华西医院、中南大学湘雅医院等全 国 26 家临床试验中心组织召开了关于开展"以注射用达托霉素为对照，初步探 索静脉输注不同剂量的 YB211 治疗成人急性细菌性皮肤及皮肤结构感染受试者 的有效性和安全性的随机、盲法、阳性药平行对照、多中心的Ⅱ期临床试验"的 项目启动会。现将主要相关情况公告如下： 一、临床试验项目基本情况 1、YB211项目是具有全新化学结构的环脂肽类1类化药新药，其化合物、制 备方法等核心技术均已获得国际和国内发明专利授权与全球独家许可。本药品申 请适应症为对本品敏感的革兰氏阳性病原菌所致的急性细菌性皮肤及皮肤结构 感染（ABSSSI），其研 ...

Core Viewpoint - The announcement indicates that Jiuzhitang's subsidiary Youbo Pharmaceutical has initiated a Phase II clinical trial for the new drug YB211, which targets acute bacterial skin and skin structure infections caused by Gram-positive pathogens [1] Group 1: Clinical Trial Details - The clinical trial kickoff meeting was held on May 24, 2025, with 26 clinical trial centers, including Fudan University Huashan Hospital [1] - YB211 is a novel cyclic lipopeptide with a new chemical structure, and the trial will compare its efficacy against the control drug Daptomycin in adult patients [1] - The trial consists of two parts: dose exploration and pharmacokinetic studies [1] Group 2: Regulatory Approvals - Youbo Pharmaceutical received the clinical trial approval notice from the National Medical Products Administration on February 6, 2025 [1] - The company obtained the ethics review committee's approval by the end of April [1] Group 3: Impact on Company Performance - The initiation of the clinical trial is expected to advance the research and evaluation progress of the new drug YB211 [1] - However, it is noted that there will be no significant impact on the company's operating performance in the short term [1]

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2025-045 九芝堂股份有限公司 关于对深圳证券交易所 2024 年年报问询函回复的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 九芝堂股份有限公司（以下简称"公司"、"本公司"）前期已收到并回复深圳 证券交易所《关于对九芝堂股份有限公司 2024 年年报的问询函》，本公司现将 回函情况公告如下： "公司""本公司""九芝堂"：九芝堂股份有限公司 "博搏医药"：牡丹江博搏医药有限责任公司 "友搏药业"：牡丹江友搏药业有限责任公司 "成都九芝堂"：成都九芝堂金鼎药业有限公司 "迪龙制药"：黑龙江迪龙制药有限公司 "并购基金"：珠海横琴九芝堂雍和启航股权投资基金（有限合伙） "九芝堂医药"：湖南九芝堂医药有限公司 "Stemedica"：Stemedica Cell Technologies Inc. 一、公司近年业绩持续下滑。年报显示，2022 年至 2024 年，你公司实现营 业收入分别为 30.33 亿元、29.61 亿元和 23.71 亿元，归母净利润分别为 3.58 亿 元、2.9 ...

Group 1 - As of May 16, three ST companies, *ST Aonong, ST Muyao, and *ST Kexin, announced the removal of their ST labels, bringing the total number of companies that have "un-capped" this year to over 20 [1] - In April and May, three listed companies from Hunan successfully removed their ST labels, with two more applying for the same [1] - The three Hunan companies that successfully "un-capped" are Bubugao, Jiuzhitang, and Youkeshu [1] Group 2 - ST Bubugao successfully "un-capped" on April 21, attributed to successful restructuring and the introduction of the Pang Donglai model, enhancing its competitive advantage [1] - ST Bubugao's fresh product category gross margin increased to 22%, exceeding the industry average by 15 percentage points, and its unique brand ratio in shopping centers is expected to reach 31% by 2024 [1] - For Q1 2025, ST Bubugao reported earnings per share of 0.04 yuan and a net profit of 119.04 million yuan, with a year-on-year growth rate of 488.44% [1] Group 3 - ST Jiuzhitang successfully "un-capped" on May 7, focusing on the production and sales of hepatitis and blood supplement series drugs [2] - The company rectified internal control deficiencies that led to a negative audit opinion last year, and announced a cash dividend of 3 yuan per 10 shares, totaling 250 million yuan [2] Group 4 - *ST Youkeshu completed its restructuring and changed its name to "Youkeshu," focusing on B2C cross-border e-commerce [2] - The company reported a debt restructuring gain of 210 million yuan, with a net profit of 17,290 yuan for Q1 2025, reflecting a year-on-year growth rate of 105.80% [2] Group 5 - *ST Kaiyuan announced a cash asset donation of 230 million yuan from an affiliate, leading to a positive net asset position by the end of 2024 [3] - *ST Jingfeng is in the pre-restructuring phase and has applied to remove its delisting risk warning after achieving a positive net asset position for 2024 [3]

| 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 300740 | 水羊股 份 | 7.34 | 11.92 | 1365.96 | 2.37 | | 002762 | *ST金 比 | 1.87 | 6.12 | 764.00 | 12.09 | | 002172 | 澳洋健 康 | -1.64 | 5.20 | 490.76 | 3.40 | | 600572 | 康恩贝 | 0.00 | 0.81 | 453.06 | 4.92 | | 002566 | 益盛药 业 | 0.56 | 2.84 | 449.27 | 9.45 | | 000516 | 国际医 学 | -2.10 | 1.02 | 173.25 | 1.49 | | 603139 | 康惠制 | -1.57 | 1.79 | -62.03 | -1.77 | | | 药 | | | | | | 000615 | *ST 美 | 0.63 | 1.59 ...

Group 1: Company Performance and Financials - In 2024, the company achieved operating revenue of 2.371 billion yuan and a net profit attributable to shareholders of 216 million yuan, with cash flow from operating activities increasing by 83.14% to 199 million yuan [2] - The company aims to maintain high-quality development despite challenges from rising raw material prices, focusing on product-centric strategies and diversifying its product portfolio [2][3] Group 2: Innovation and R&D - The company is actively developing its stem cell research, with ongoing clinical trials for treatments related to ischemic stroke and autoimmune diseases, having enrolled 31 and 8 participants respectively [3] - A GMP-compliant stem cell R&D production base has been established, meeting both Chinese and U.S. drug application standards, and the company has received CNAS certification [3] Group 3: Shareholder Returns - The company announced a cash dividend of 3 yuan per 10 shares for the 2024 fiscal year, with the dividend record date on May 7 and payment on May 8 [4] - Cumulatively, the company has distributed over 4 billion yuan in dividends since its listing [5] Group 4: Corporate Governance - In January, the company underwent a change in control, with the Heilongjiang Provincial State-owned Assets Supervision and Administration Commission becoming the new actual controller, which is expected to enhance operational efficiency and market competitiveness [6]

Summary of Key Points Core Insights - The report highlights various companies undergoing temporary suspensions of trading due to different reasons, including financial disclosures and potential delisting risks. This indicates a volatile market environment where investor confidence may be affected by such events [2][3][4]. Company Specifics - ST Jiuzhi (000989) announced a temporary suspension of trading on May 6, 2025, due to the cancellation of other risk warnings [2]. - In the case of ST Gongzhi (000584), trading was suspended due to a risk warning regarding potential delisting, effective from April 28, 2025 [2]. - ST Hengli (000622) and Tianmao Group (000627) also faced trading suspensions due to their inability to disclose periodic reports within the legal timeframe, effective from May 6, 2025 [2]. - Binhai Energy (000695) is undergoing a trading suspension as it plans to issue shares for asset acquisition and raise matching funds, effective from April 30, 2025 [2]. - Electric Power Investment Energy (002128) is also suspended for similar reasons related to asset acquisition and related party transactions, effective from May 6, 2025 [2]. Industry Context - The report reflects a broader trend in the market where companies are facing increased scrutiny and regulatory challenges, leading to trading suspensions. This could signal potential investment risks in the affected sectors [2][3][4].

证券代码：000989 证券简称：ST九芝 公告编号：2025-044 九芝堂股份有限公司 公告文件 关于撤销其他风险警示暨停复牌的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 特别提示： 1、九芝堂股份有限公司（以下简称"公司"）股票交易于 2025 年 5 月 6 日 停牌一天，于 2025 年 5 月 7 日开市起复牌。 2、公司股票自 5 月 7 日开市起撤销其他风险警示，证券简称由 "ST 九芝" 变更为"九芝堂"，证券代码仍为"000989"，撤销其他风险警示后，公司股票交 易日的涨跌幅限制由 5%变更为 10% 。 一、股票种类、简称、证券代码、涨跌幅以及股票停复牌安排 1、股票种类：人民币普通股； 2、股票简称：由"ST 九芝"变更为"九芝堂"； 3、证券代码：仍为"000989"； 4、撤销其他风险警示的起始日：2025 年 5 月 7 日； 5、公司股票停复牌安排：公司股票将于 2025 年 5 月 6 日停牌一天，并于 2025 年 5 月 7 日开市起复牌； 公告文件 出具无法表示意见或者否定意见的内部控制审计报告或者鉴证报告， ...